The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developing a clinic-bound therapeutic. Join Dr. Igor Oruetexebarria, senior scientist at Kuopio Center for Gene and Cell Therapy, as he walks through some of the current challenges in the field of gene therapy AAV development, and explains how the nanoDSF and DLS capabilities of the Prometheus Panta have improved the outcomes for his vector candidates.
New advances in gene therapy have triggered a resurgence of interest in the field. Though gene therapy offe...
Trying to develop safe and effective gene therapies?
Biophysical methods can help.
See more related content
New advances in gene therapy have triggered a resurgence of interest in the field. Though gene therapy offers exciting potential for the treatment of both monogenic disorders as well as more genetical
Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns such as serotype, storage stability, expression method, and genetic fill level must be addres
Gene therapy—a type of DNA-based medicine that utilizes a virus to insert a healthy gene into cells to replace a mutated, disease-causing variant has emerged as one of the most promising medical treat
Gene therapy promises to treat and potentially cure a disease by correcting its underlying genetic cause. While gene therapies that utilize AAV vectors have shown encouraging results —including a few